Sort
21,281 grants matching “influenza”
Leveraging Molecular Technologies to Improve Diagnosis and Management of Pediatric Acute Respiratory Illness in Resource-Constrained Settings
$203,605Emily Jane Ciccone · Univ Of North Carolina Chapel Hill · K23 · FY2024 · AI
Anti-inflammatory Assay for Cystic Fibrosis
$203,546Rangan Maitra · Research Triangle Institute · R21 · FY2007 · NS
PRENATAL SENSITIZATION TO W BANCROFTI
$203,502Case Western Reserve University · U19 · FY2000 · AI
Targeting viral alkaline nucleases for the development of broad spectrum anti-herpesvirus therapeutics
$203,500Sandra K Weller · University Of Connecticut Sch Of Med/Dnt · R21 · FY2020 · AI
Novel TLR-4 Agonists as Vaccine Adjuvants
$203,485Alan Thomas Johnson · Hawaii Biotech, Inc. · R43 · FY2023 · AI
Discovery of small molecules to block fusion and entry of dengue and other env vi
$203,405Stephen C Harrison · Harvard Medical School · U54 · FY2013 · AI
Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases
$203,359Clifford Lane · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Effects of Aging on Lymphoid Biased Hematopoietic Stem Cells
$203,280Kenneth Allan Dorshkind · University Of California Los Angeles · R56 · FY2016 · AG
DEVELOPMENT AND PERSISTENCE OF MEMORY T LYMPHOCYTES
$203,259University Of Chicago · R01 · FY2000 · AI
Effect of allergic asthma on CD8+ TRM-mediated protection from infection
$203,200Shannon K Bromley · Massachusetts General Hospital · R21 · FY2021 · AI
Programming designer DNA nanostructures for blocking enveloped viral infection
$203,149Weishan Huang · Louisiana State Univ A&M Col Baton Rouge · R21 · FY2023 · AI
The Oropharyngeal Microbiome in COVID-19
$203,125Ronald G Collman · University Of Pennsylvania · R21 · FY2023 · DE
Mechanism for non-templated initiation by a paramyxovirus polymerase
$203,125Rachel Fearns · Boston University Medical Campus · R21 · FY2009 · AI
Atypical B Cells: Origin and Autoreactivity
$203,094Joseph E Craft · Yale University · R21 · FY2025 · AI
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
$203,040Andrea Gambotto · University Of Pittsburgh At Pittsburgh · R21 · FY2016 · AI
How does Cytomegalovirus use interferon lambda for optimal spread
$202,950Christopher Norbury · Pennsylvania State Univ Hershey Med Ctr · R21 · FY2023 · AI
A VSV vectored vaccine for emergent tick-born phleboviruses
$202,917Paul F Bates · University Of Pennsylvania · R21 · FY2021 · AI
Summer Institute in Statistics and Modeling in Infectious Diseases
$202,875M Elizabeth Halloran · University Of Washington · R25 · FY2020 · AI
Psychogenic illness in response to pandemic or mass biological exposure: Developm
$202,836Joan E Broderick · State University New York Stony Brook · R21 · FY2010 · LM
Models for synthesising molecular, clinical and epidemiological data, and transla
$202,814Neil Morris Ferguson · Imperial College Of Science, Technology And Medicine · U01 · FY2017 · GM
The effect of human pre-exposure history on antigenic drift of influenza viruses
$202,789Scott Eric Hensley · Wistar Institute · R01 · FY2016 · AI
Core C: Immune Assay
$202,783Boris Michael Hartmann · Icahn School Of Medicine At Mount Sinai · U19 · FY2017 · AI
Determining the role of NLRP3 on the placement and protective potential of CD73+ BRMs post influenza infection
$202,725S Rameeza Allie · Pennsylvania State Univ Hershey Med Ctr · R21 · FY2021 · AI
Emerging Infectious Diseases Training Program
$202,626Kathleen A. McDonough · Wadsworth Center · T32 · FY2012 · AI
Influenza & COVID Obstetric and Perinatal Epidemiology Study in India
$202,513Patricia L Hibberd · Boston University Medical Campus · R01 · FY2025 · HD